|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.838 EUR | -0.81% |
|
-2.28% | -17.40% |
| 14/07 | Where would AI lead Pharma in the long run? | ![]() |
| 01/07 | Spanish stocks - Factors to watch on July 1 | RE |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biopharma | 381.5Cr | 500.54Cr | 555.83Cr | 614.26Cr | 648.7Cr | |||||
Total Assets | 949.92Cr | 1.32TCr | 1.34TCr | 1.43TCr | 1.34TCr | |||||
CAPEX | -35Cr | - | - | - | - | |||||
EBITDA | - | - | - | - | 174.6Cr | |||||
D&A | 23Cr | 29Cr | 33Cr | 33Cr | 34Cr | |||||
Operating Income | 66Cr | 79Cr | 90Cr | 127.12Cr | 140.1Cr | |||||
Bio Supplies | 23Cr | 15Cr | 16Cr | 22Cr | 15Cr | |||||
Total Assets | 10Cr | 34Cr | 38Cr | 35Cr | 28Cr | |||||
CAPEX | -1.38Cr | - | - | - | - | |||||
EBITDA | - | - | - | - | 4.9Cr | |||||
D&A | 29.48L | 57.59L | 92.8L | 93.05L | 90L | |||||
Operating Income | 4.6Cr | 11Cr | 4.36Cr | 4.78Cr | 4Cr | |||||
Raw Materials and Others | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Medical Testing, Analyzing, and Diagnostic Equipment | ||||||||||
Diagnostic | 78Cr | 67Cr | 67Cr | 64Cr | 64Cr | |||||
Total Assets | 351.4Cr | 368.16Cr | 352.89Cr | 375.48Cr | 338.9Cr | |||||
CAPEX | -2Cr | - | - | - | - | |||||
EBITDA | - | - | - | - | 16Cr | |||||
D&A | 8.86Cr | 6.47Cr | 6.58Cr | 6.45Cr | 6.3Cr | |||||
Operating Income | 15Cr | 13Cr | 11Cr | 11Cr | 9.6Cr | |||||
Pharmaceutical Contract Manufacturing Services | ||||||||||
Others | 3.96Cr | 25Cr | 20Cr | 21Cr | 24Cr | |||||
Total Assets | 247.25Cr | 268.02Cr | 266.24Cr | 89Cr | 86Cr | |||||
CAPEX | -1.6Cr | - | - | - | - | |||||
EBITDA | - | - | - | - | -2.6Cr | |||||
D&A | 69.78L | 2.04Cr | 1.62Cr | 1.57Cr | 1.6Cr | |||||
Operating Income | -5.86Cr | -4.68Cr | 66.32L | 3.94Cr | -4.2Cr | |||||
Intersegments | -6.75Cr | -89.48L | - | - | - | |||||
Total Assets | -4Cr | -69.97L | - | - | - | |||||
Operating Income | -1.09Cr | 3.54Cr | 69.79L | - | - | |||||
Operating Income | -19Cr | -22Cr | -27Cr | -28Cr | -25Cr | |||||
EBITDA | - | - | - | - | -24Cr | |||||
Total Assets | - | - | - | - | 30Cr | |||||
Total Assets | 341.78Cr | 160.85Cr | 140.09Cr | 211.01Cr | 147.1Cr | |||||
CAPEX | -5.54Cr | - | - | - | - | |||||
D&A | 2.11Cr | 2.29Cr | 2.21Cr | 2.06Cr | 1.7Cr | |||||
Pharmaceutical Products | ||||||||||
Hospital | 14Cr | - | - | - | - | |||||
Total Assets | 27Cr | - | - | - | - | |||||
CAPEX | -1.26Cr | - | - | - | - | |||||
D&A | 1.21Cr | - | - | - | - | |||||
Operating Income | -77.35L | - | - | - | - |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
USA and Canada | 315.45Cr | 385.56Cr | 389.9Cr | 408.7Cr | 425.3Cr | |||||
Total Assets | 1.05TCr | 1.16TCr | 1.08TCr | 1.18TCr | 1.07TCr | |||||
CAPEX | -30Cr | - | - | - | - | |||||
Rest of World | 87Cr | 117.62Cr | 143.71Cr | 158.4Cr | 165.7Cr | |||||
Total Assets | 222.29Cr | 221.66Cr | 223.66Cr | 40Cr | 46Cr | |||||
CAPEX | -97.58L | - | - | - | - | |||||
Rest of European Union | 54Cr | 71Cr | 89Cr | 111.83Cr | 119.6Cr | |||||
Total Assets | 539.34Cr | 660.03Cr | 705.45Cr | 758.43Cr | 694.3Cr | |||||
CAPEX | -9.14Cr | - | - | - | - | |||||
Spain | 36Cr | 32Cr | 36Cr | 42Cr | 42Cr | |||||
Total Assets | 109.24Cr | 115.61Cr | 119.06Cr | 163.55Cr | 163.9Cr | |||||
CAPEX | -7.1Cr | - | - | - | - | |||||
Unallocated Raw Material & Others | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - |
- Stock Market
- Stocks
- GRF Stock
- Financials Grifols, S.A.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
















